{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T15:27:58Z","timestamp":1774020478225,"version":"3.50.1"},"reference-count":97,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T00:00:00Z","timestamp":1719446400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"IPO Porto","award":["PI61-CI-IPOP-22-2015"],"award-info":[{"award-number":["PI61-CI-IPOP-22-2015"]}]},{"name":"IPO Porto","award":["2020.08969.BD"],"award-info":[{"award-number":["2020.08969.BD"]}]},{"name":"IPO Porto","award":["UIDB\/00776\/2020-3"],"award-info":[{"award-number":["UIDB\/00776\/2020-3"]}]},{"DOI":"10.13039\/501100001871","name":"European Social Funds (FSE) and national funds of MCTES","doi-asserted-by":"publisher","award":["PI61-CI-IPOP-22-2015"],"award-info":[{"award-number":["PI61-CI-IPOP-22-2015"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"European Social Funds (FSE) and national funds of MCTES","doi-asserted-by":"publisher","award":["2020.08969.BD"],"award-info":[{"award-number":["2020.08969.BD"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"European Social Funds (FSE) and national funds of MCTES","doi-asserted-by":"publisher","award":["UIDB\/00776\/2020-3"],"award-info":[{"award-number":["UIDB\/00776\/2020-3"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"FCT\/MCTES","doi-asserted-by":"publisher","award":["PI61-CI-IPOP-22-2015"],"award-info":[{"award-number":["PI61-CI-IPOP-22-2015"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"FCT\/MCTES","doi-asserted-by":"publisher","award":["2020.08969.BD"],"award-info":[{"award-number":["2020.08969.BD"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"FCT\/MCTES","doi-asserted-by":"publisher","award":["UIDB\/00776\/2020-3"],"award-info":[{"award-number":["UIDB\/00776\/2020-3"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Ovarian cancer (OC) is the deadliest gynaecological malignancy. Identifying new prognostic biomarkers is an important research field. Haemostatic components together with leukocytes can drive cancer progression while increasing the susceptibility to venous thromboembolism (VTE) through immunothrombosis. Unravelling the underlying complex interactions offers the prospect of uncovering relevant OC prognostic biomarkers, predictors of cancer-associated thrombosis (CAT), and even potential targets for cancer therapy. Thus, this study evaluated the expression of F3, F5, F8, F13A1, TFPI1, and THBD in peripheral blood cells (PBCs) of 52 OC patients. Those with VTE after tumour diagnosis had a worse overall survival (OS) compared to their counterparts (mean OS of 13.8 \u00b1 4.1 months and 47.9 \u00b1 5.7 months, respectively; log-rank test, p = 0.001). Low pre-chemotherapy F3 and F8 expression levels were associated with a higher susceptibility for OC-related VTE after tumour diagnosis (\u03c72, p &lt; 0.05). Regardless of thrombogenesis, patients with low baseline F8 expression had a shorter progression-free survival (PFS) than their counterparts (adjusted hazard ratio (aHR) = 2.54; p = 0.021). Among those who were not under platelet anti-aggregation therapy, low F8 levels were also associated with a shorter OS (aHR = 6.16; p = 0.006). Moving forward, efforts should focus on external validation in larger cohorts.<\/jats:p>","DOI":"10.3390\/cancers16132356","type":"journal-article","created":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T08:57:50Z","timestamp":1719478670000},"page":"2356","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Haemostatic Gene Expression in Cancer-Related Immunothrombosis: Contribution for Venous Thromboembolism and Ovarian Tumour Behaviour"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3680-7757","authenticated-orcid":false,"given":"Val\u00e9ria","family":"Tavares","sequence":"first","affiliation":[{"name":"Molecular Oncology and Viral Pathology Group, Research Center of IPO Porto (CI-IPOP)\/Pathology and Laboratory Medicine Dep., Clinical Pathology SV\/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)\/Porto Comprehensive Cancer Centre (Porto. CCC), 4200-072 Porto, Portugal"},{"name":"ICBAS\u2014Instituto de Ci\u00eancias Biom\u00e9dicas Abel Salazar, Universidade do Porto, 4050-313 Porto, Portugal"},{"name":"Faculty of Medicine of the University of Porto (FMUP), 4200-072 Porto, Portugal"}]},{"given":"Joana","family":"Savva-Bordalo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Portuguese Institute of Oncology of Porto (IPO Porto), 4200-072 Porto, Portugal"}]},{"given":"Mariana","family":"Rei","sequence":"additional","affiliation":[{"name":"Department of Gynaecology, Portuguese Institute of Oncology of Porto (IPO Porto), 4200-072 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9150-4180","authenticated-orcid":false,"given":"Joana","family":"Liz-Pimenta","sequence":"additional","affiliation":[{"name":"Faculty of Medicine of the University of Porto (FMUP), 4200-072 Porto, Portugal"},{"name":"Department of Medical Oncology, Centro Hospitalar de Tr\u00e1s-os-Montes e Alto Douro (CHTMAD), 5000-508 Vila Real, Portugal"}]},{"given":"Joana","family":"Assis","sequence":"additional","affiliation":[{"name":"Clinical Research Unit, Research Center of IPO Porto (CI-IPOP)\/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)\/Porto Comprehensive Cancer Center (Porto. CCC), 4200-072 Porto, Portugal"}]},{"given":"Deolinda","family":"Pereira","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Portuguese Institute of Oncology of Porto (IPO Porto), 4200-072 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3010-8373","authenticated-orcid":false,"given":"Rui","family":"Medeiros","sequence":"additional","affiliation":[{"name":"Molecular Oncology and Viral Pathology Group, Research Center of IPO Porto (CI-IPOP)\/Pathology and Laboratory Medicine Dep., Clinical Pathology SV\/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)\/Porto Comprehensive Cancer Centre (Porto. CCC), 4200-072 Porto, Portugal"},{"name":"ICBAS\u2014Instituto de Ci\u00eancias Biom\u00e9dicas Abel Salazar, Universidade do Porto, 4050-313 Porto, Portugal"},{"name":"Faculty of Medicine of the University of Porto (FMUP), 4200-072 Porto, Portugal"},{"name":"Faculty of Health Sciences, Fernando Pessoa University, 4200-150 Porto, Portugal"},{"name":"Research Department, Portuguese League Against Cancer (NRNorte), 4200-172 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2024,6,27]]},"reference":[{"key":"ref_1","unstructured":"Ferlay, J., Ervik, M., Lam, F., Laversanne, M., Colombet, M., Mery, L., Pi\u00f1eros, M., Znaor, A., Soerjomataram, I., and Bray, F. Global Cancer Observatory: Cancer Today, International Agency for Research on Cancer. Available online: https:\/\/gco.iarc.fr\/today."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13048-022-01020-1","article-title":"Maintenance therapy for newly diagnosed epithelial ovarian cancer\u2014A review","volume":"15","author":"Nag","year":"2022","journal-title":"J. Ovarian Res."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Tavares, V., Marques, I.S., Melo, I.G.d., Assis, J., Pereira, D., and Medeiros, R. (2024). Paradigm Shift: A Comprehensive Review of Ovarian Cancer Management in an Era of Advancements. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25031845"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Oncul, S., and Cho, M.S. (2023). Interactions between platelets and tumor microenvironment components in ovarian cancer and their implications for treatment and clinical outcomes. Cancers, 15.","DOI":"10.3390\/cancers15041282"},{"key":"ref_5","first-page":"3958","article-title":"Human kallikrein 5: A potential novel serum biomarker for breast and ovarian cancer","volume":"63","author":"Yousef","year":"2003","journal-title":"Cancer Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.trsl.2020.06.012","article-title":"Mechanisms and biomarkers of cancer-associated thrombosis","volume":"225","author":"Kim","year":"2020","journal-title":"Transl. Res."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Neto, B.V., Tavares, V., da Silva, J.B., Liz-Pimenta, J., Marques, I.S., Salgado, L., Carvalho, L., Pereira, D., and Medeiros, R. (2024). Haemostatic gene variations in cervical cancer-associated venous thrombosis: Considerations for clinical strategies. J. Thromb. Thrombolysis, 1\u201313.","DOI":"10.1007\/s11239-024-02983-2"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41572-022-00336-y","article-title":"Cancer-associated venous thromboembolism","volume":"8","author":"Khorana","year":"2022","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Glassman, D., Bateman, N.W., Lee, S., Zhao, L., Yao, J., Tan, Y., Ivan, C., Rangel, K.M., Zhang, J., and Conrads, K.A. (2022). Molecular correlates of venous thromboembolism (VTE) in ovarian cancer. Cancers, 14.","DOI":"10.3390\/cancers14061496"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"103989","DOI":"10.1016\/j.critrevonc.2023.103989","article-title":"Thrombosis and cachexia in cancer: Two partners in crime?","volume":"186","author":"Tavares","year":"2023","journal-title":"Crit. Rev. Oncol.\/Hematol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Heestermans, M., Poenou, G., Duchez, A.-C., Hamzeh-Cognasse, H., Bertoletti, L., and Cognasse, F. (2022). Immunothrombosis and the role of platelets in venous thromboembolic diseases. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232113176"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.thromres.2021.12.013","article-title":"Crosstalk between hemostasis and immunity in cancer pathogenesis","volume":"213","author":"Palumbo","year":"2022","journal-title":"Thromb. Res."},{"key":"ref_13","first-page":"753","article-title":"The role of leukocytes in thrombosis","volume":"128","author":"Swystun","year":"2016","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s12943-022-01588-8","article-title":"Potential clinical utility of liquid biopsies in ovarian cancer","volume":"21","author":"Zhu","year":"2022","journal-title":"Mol. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.3324\/haematol.2016.147405","article-title":"Joint effects of cancer and variants in the factor 5 gene on the risk of venous thromboembolism","volume":"101","author":"Gran","year":"2016","journal-title":"Haematologica"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Tavares, V., Neto, B.V., Marques, I.S., Assis, J., Pereira, D., and Medeiros, R. (2023). Cancer-associated thrombosis: What about microRNAs targeting the tissue factor coagulation pathway?. Biochim. Biophys. Acta BBA-Rev. Cancer, 1879.","DOI":"10.1016\/j.bbcan.2023.189053"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1055\/s-0039-1687895","article-title":"Role of tissue factor in tumor progression and cancer-associated thrombosis","volume":"45","author":"Rondon","year":"2019","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.jtha.2022.11.033","article-title":"Peripheral blood mononuclear cell tissue factor (F3 gene) transcript levels and circulating extracellular vesicles are elevated in severe coronavirus 2019 (COVID-19) disease","volume":"21","author":"Girard","year":"2023","journal-title":"J. Thromb. Haemost."},{"key":"ref_19","first-page":"5242","article-title":"Human platelets synthesize and express functional tissue factor","volume":"109","author":"Panes","year":"2007","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/srep00787","article-title":"Characterization of coagulation factor synthesis in nine human primary cell types","volume":"2","author":"Dashty","year":"2012","journal-title":"Sci. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"103971","DOI":"10.1016\/j.isci.2022.103971","article-title":"Coagulation factor V is a T-cell inhibitor expressed by leukocytes in COVID-19","volume":"25","author":"Wang","year":"2022","journal-title":"iScience"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/jth.12412","article-title":"Human liver sinusoidal endothelial cells but not hepatocytes contain factor VIII","volume":"12","author":"Shahani","year":"2014","journal-title":"J. Thromb. Haemost."},{"key":"ref_23","first-page":"11","article-title":"The factor VIII protein and its function","volume":"63","author":"Ciach","year":"2016","journal-title":"Acta Biochim. Pol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"881","DOI":"10.3324\/haematol.2014.123117","article-title":"Extrahepatic sources of factor VIII potentially contribute to the coagulation cascade correcting the bleeding phenotype of mice with hemophilia A","volume":"100","author":"Zanolini","year":"2015","journal-title":"Haematologica"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1055\/s-0037-1613622","article-title":"Messenger RNA profiling of human platelets by microarray hybridization","volume":"90","author":"Bugert","year":"2003","journal-title":"Thromb. Haemost."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Alshehri, F.S., Whyte, C.S., and Mutch, N.J. (2021). Factor XIII-A: An indispensable \u201cfactor\u201d in haemostasis and wound healing. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22063055"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1182\/blood-2020-141382","article-title":"Transcription factor RUNX1 regulates factor FXIIIA subunit (F13A1) expression in megakaryocytic cells and platelet F13A1 expression is downregulated in RUNX1 haplodeficiency","volume":"136","author":"Songdej","year":"2020","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/2756781","article-title":"Peroxisome proliferator-activated receptor \u03b3 induces the expression of tissue factor pathway inhibitor-1 (TFPI-1) in human macrophages","volume":"2016","author":"Copin","year":"2016","journal-title":"PPAR Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1182\/blood.V80.5.1254.1254","article-title":"Human neutrophils synthesize thrombomodulin that does not promote thrombin-dependent protein C activation","volume":"80","author":"Conway","year":"1992","journal-title":"Blood"},{"key":"ref_30","first-page":"148","article-title":"Exploring traditional and nontraditional roles for thrombomodulin","volume":"132","author":"Loghmani","year":"2018","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/jrr\/rru074","article-title":"Evaluation of endogenous control gene(s) for gene expression studies in human blood exposed to 60 Co \u03b3-rays ex vivo","volume":"56","author":"Vaiphei","year":"2015","journal-title":"J. Radiat. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4349","DOI":"10.1016\/j.clnu.2021.01.011","article-title":"Diurnal variation in gene expression of human peripheral blood mononuclear cells after eating a standard meal compared with a high protein meal: A cross-over study","volume":"40","author":"Davis","year":"2021","journal-title":"Clin. Nutr."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/s41598-023-27460-3","article-title":"Identification of stable reference genes in peripheral blood mononuclear cells from type 2 diabetes mellitus patients","volume":"13","author":"Hazarika","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/ijgo.13878","article-title":"Cancer of the ovary, fallopian tube, and peritoneum: 2021 update","volume":"155","author":"Berek","year":"2021","journal-title":"Int. J. Gynecol. Obstet."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Tavares, V., Pinto, R., Assis, J., Pereira, D., and Medeiros, R. (2020). Venous thromboembolism GWAS reported genetic makeup and the hallmarks of cancer: Linkage to ovarian tumour behaviour. Biochim. Biophys. Acta BBA-Rev. Cancer, 1873.","DOI":"10.1016\/j.bbcan.2019.188331"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/imr.13178","article-title":"Neutrophil interactions with T cells, platelets, endothelial cells, and of course tumor cells","volume":"314","author":"Segal","year":"2023","journal-title":"Immunol. Rev."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Casta\u00f1o, M., Tom\u00e1s-P\u00e9rez, S., Gonz\u00e1lez-Cant\u00f3, E., Aghababyan, C., Mascar\u00f3s-Mart\u00ednez, A., Santonja, N., Herreros-Pomares, A., Oto, J., Medina, P., and G\u00f6tte, M. (2023). Neutrophil extracellular traps and cancer: Trapping our attention with their involvement in ovarian cancer. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24065995"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Pankowska, K.A., B\u0119dkowska, G.E., Chociej-Stypu\u0142kowska, J., Rusak, M., D\u0105browska, M., and Osada, J. (2023). Crosstalk of immune cells and platelets in an ovarian cancer microenvironment and their prognostic significance. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24119279"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"515","DOI":"10.4103\/0019-5049.144643","article-title":"Overview of the coagulation system","volume":"58","author":"Palta","year":"2014","journal-title":"Indian J. Anaesth."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1080\/09537100801990582","article-title":"\u201cMessage in the platelet\u201d\u2013more than just vestigial mRNA!","volume":"19","author":"Harrison","year":"2008","journal-title":"Platelets"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ejogrb.2013.06.004","article-title":"Venous thromboembolism in ovarian cancer: Incidence, risk factors and impact on survival","volume":"170","author":"Saadeh","year":"2013","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.thromres.2019.07.027","article-title":"Venous thromboembolism in epithelial ovarian cancer. A prospective cohort study","volume":"181","author":"Kahr","year":"2019","journal-title":"Thromb. Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1136\/ijgc-2019-000980","article-title":"Incidence of venous thromboembolism among patients receiving neoadjuvant chemotherapy for advanced epithelial ovarian cancer","volume":"30","author":"Salinaro","year":"2020","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_45","first-page":"2374716","article-title":"Meta-Analysis of VTE Risk: Ovarian Cancer Patients by Stage, Histology, Cytoreduction, and Ascites at Diagnosis","volume":"2020","author":"Weeks","year":"2020","journal-title":"Obs. Gynecol. Int."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ygyno.2021.07.030","article-title":"Risk of venous thromboembolism in ovarian cancer patients receiving neoadjuvant chemotherapy","volume":"163","author":"Basaran","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1111\/aogs.14246","article-title":"Venous thromboembolism in women with ovarian cancer undergoing neoadjuvant chemotherapy prior to cytoreductive surgery: A retrospective study","volume":"100","author":"Oxley","year":"2021","journal-title":"Acta Obstet. Gynecol. Scand."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"A1","DOI":"10.1016\/j.ygyno.2023.08.003","article-title":"Universal thromboprophylaxis in ovarian cancer patients before and after surgery?","volume":"176","author":"Moufarrij","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.thromres.2010.05.012","article-title":"Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapy","volume":"126","author":"Connolly","year":"2010","journal-title":"Thromb. Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1182\/blood-2018-99-120193","article-title":"Leukocytosis, but Not Thrombocytosis, May Constitute a Prothrombotic Pathway in Women with Ovarian Cancer: A Cohort Study","volume":"132","author":"Salazar","year":"2018","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.ygyno.2013.09.005","article-title":"Venous thromboembolism during primary treatment of ovarian clear cell carcinoma is associated with decreased survival","volume":"131","author":"Diaz","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.thromres.2015.11.030","article-title":"Venous thromboembolism at time of diagnosis of ovarian cancer: Survival differs in symptomatic and asymptomatic cases","volume":"137","author":"Heath","year":"2016","journal-title":"Thromb. Res."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Liz-Pimenta, J., Tavares, V., Grama\u00e7a, J., Rato, J., Menezes, M., Baleiras, M., Guedes, H., Reis, J., Guedes, C., and Gomes, R. (2024). Primary thromboprophylaxis in cancer outpatients\u2013real-world evidence. J. Thromb. Thrombolysis, 1\u201310.","DOI":"10.1007\/s11239-024-02984-1"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Hisada, Y., and Mackman, N. (2021). Tissue factor and extracellular vesicles: Activation of coagulation and impact on survival in cancer. Cancers, 13.","DOI":"10.3390\/cancers13153839"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s13045-020-00932-z","article-title":"Beyond thrombosis: The impact of tissue factor signaling in cancer","volume":"13","author":"Unruh","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Hisada, Y., and Mackman, N. (2019). Tissue factor and cancer: Regulation, tumor growth, and metastasis. Seminars in Thrombosis and Hemostasis, Thieme Medical Publishers.","DOI":"10.1055\/s-0039-1687894"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1055\/a-2091-7006","article-title":"Monocyte tissue factor expression: Lipopolysaccharide induction and roles in pathological activation of coagulation","volume":"123","author":"Sachetto","year":"2023","journal-title":"Thromb. Haemost."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Singh, A.K., and Malviya, R. (2022). Coagulation and inflammation in cancer: Limitations and prospects for treatment. Biochim. Biophys. Acta BBA-Rev. Cancer, 1877.","DOI":"10.1016\/j.bbcan.2022.188727"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1007\/s10620-008-0265-3","article-title":"Deep vein thrombosis and pulmonary embolism in cirrhosis patients","volume":"53","author":"Gulley","year":"2008","journal-title":"Dig. Dis. Sci."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41397-020-00201-9","article-title":"Implications of venous thromboembolism GWAS reported genetic makeup in the clinical outcome of ovarian cancer patients","volume":"21","author":"Tavares","year":"2021","journal-title":"Pharmacogenom. J."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Marques, I.S., Tavares, V., Savva-Bordalo, J., Rei, M., Liz-Pimenta, J., de Melo, I.G., Assis, J., Pereira, D., and Medeiros, R. (2023). Long Non-Coding RNAs: Bridging Cancer-Associated Thrombosis and Clinical Outcome of Ovarian Cancer Patients. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25010140"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1160\/TH16-10-0784","article-title":"IL-33 stimulates the release of procoagulant microvesicles from human monocytes and differentially increases tissue factor in human monocyte subsets","volume":"117","author":"Stojkovic","year":"2017","journal-title":"Thromb. Haemost."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2741\/e376","article-title":"Tissue factor in blood cells and endothelial cells","volume":"4","author":"Osterud","year":"2012","journal-title":"Front. Biosci.-Elite"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"McMichael, M.A. (2022). Overview of Hemostasis. Schalm's Veterinary Hematology, Wiley.","DOI":"10.1002\/9781119500537.ch87"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1055\/s-0039-1687906","article-title":"A comprehensive overview of coagulation factor V and congenital factor V deficiency","volume":"45","author":"Tabibian","year":"2019","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/ijlh.12508","article-title":"Pro-and anticoagulant properties of factor V in pathogenesis of thrombosis and bleeding disorders","volume":"38","year":"2016","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1824644","DOI":"10.1080\/2162402X.2020.1824644","article-title":"Coagulation factor V is a marker of tumor-infiltrating immune cells in breast cancer","volume":"9","author":"Tinholt","year":"2020","journal-title":"Oncoimmunology"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1111\/jth.14151","article-title":"Subtype-specific clinical and prognostic relevance of tumor-expressed F5 and regulatory F5 variants in breast cancer: The CoCaV study","volume":"16","author":"Tinholt","year":"2018","journal-title":"J. Thromb. Haemost."},{"key":"ref_69","first-page":"2415","article-title":"Coagulation factor V mediates inhibition of tissue factor signaling by activated protein C in mice","volume":"126","author":"Liang","year":"2015","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Reddel, C.J., Tan, C.W., and Chen, V.M. (2019). Thrombin generation and cancer: Contributors and consequences. Cancers, 11.","DOI":"10.3390\/cancers11010100"},{"key":"ref_71","first-page":"3647","article-title":"Platelets and platelet-derived factor Va confer hemostatic competence in complete factor V deficiency","volume":"125","author":"Bouchard","year":"2015","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/jth.14343","article-title":"High levels of coagulation factors and venous thrombosis risk: Strongest association for factor VIII and von Willebrand factor","volume":"17","author":"Rietveld","year":"2019","journal-title":"J. Thromb. Haemost."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1161\/ATVBAHA.109.190827","article-title":"High factor VIII levels independently predict venous thromboembolism in cancer patients: The cancer and thrombosis study","volume":"29","author":"Vormittag","year":"2009","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.thromres.2020.09.021","article-title":"High plasma levels of soluble P-Selectin and Factor VIII predict venous thromboembolism in non-small cell lung cancer patients: The Thrombo-Nsclc risk score","volume":"196","author":"Rubio","year":"2020","journal-title":"Thromb. Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.thromres.2020.01.002","article-title":"Haemostatic biomarkers for prognosis and prediction of therapy response in patients with metastatic colorectal cancer","volume":"187","author":"Moik","year":"2020","journal-title":"Thromb. Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/jth.13294","article-title":"Aging and ABO blood type influence von Willebrand factor and factor VIII levels through interrelated mechanisms","volume":"14","author":"Ogiwara","year":"2016","journal-title":"J. Thromb. Haemost."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Kiouptsi, K., and Reinhardt, C. (2020). Physiological roles of the von Willebrand factor-factor VIII interaction. Vertebrate and Invertebrate Respiratory Proteins, Lipoproteins and Other Body Fluid Proteins, Springer.","DOI":"10.1007\/978-3-030-41769-7_18"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/jth.15611","article-title":"Factor VIII as a potential player in cancer pathophysiology","volume":"20","author":"Walker","year":"2022","journal-title":"J. Thromb. Haemost."},{"key":"ref_79","first-page":"68","article-title":"Factor VIII as a Novel Biomarker for Diagnosis, Prognosis, and Therapy Prediction in Human Cancer and Other Disorders","volume":"16","author":"Khalilian","year":"2023","journal-title":"Avicenna J. Med. Biotechnol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1182\/blood.V74.6.2016.2016","article-title":"Effect of aspirin on platelet-von Willebrand factor surface expression on thrombin and ADP-stimulated platelets","volume":"74","author":"Parker","year":"1989","journal-title":"Blood"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Kwon, J.E., Roh, D.E., and Kim, Y.H. (2020). The impact of moderate-dose acetylsalicylic acid in the reduction of inflammatory cytokine and prevention of complication in acute phase of Kawasaki disease: The benefit of moderate-dose acetylsalicylic acid. Children, 7.","DOI":"10.3390\/children7100185"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Byrnes, J.R., and Wolberg, A.S. (2016). Newly-recognized roles of factor XIII in thrombosis. Seminars in Thrombosis and Hemostasis, Thieme Medical Publishers.","DOI":"10.1055\/s-0036-1571343"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.thromres.2011.11.040","article-title":"Factor XIII, clot structure, thrombosis","volume":"129","author":"Bagoly","year":"2012","journal-title":"Thromb. Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s12185-012-1064-3","article-title":"Factor XIII is a key molecule at the intersection of coagulation and fibrinolysis as well as inflammation and infection control","volume":"95","author":"Ichinose","year":"2012","journal-title":"Int. J. Hematol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.3349\/ymj.2013.54.6.1394","article-title":"Relationships of coagulation factor XIII activity with cell-type and stage of non-small cell lung cancer","volume":"54","author":"Lee","year":"2013","journal-title":"Yonsei Med. J."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2147\/VHRM.S240500","article-title":"Clinical significance of factor XIII activity and monocyte-derived microparticles in cancer patients","volume":"16","author":"Sawai","year":"2020","journal-title":"Vasc. Health Risk Manag."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/8983763","article-title":"Tissue factor pathway inhibitor-1 is a valuable marker for the prediction of deep venous thrombosis and tumor metastasis in patients with lung cancer","volume":"2017","author":"Fei","year":"2017","journal-title":"BioMed Res. Int."},{"key":"ref_88","first-page":"S23","article-title":"Tissue factor pathway inhibitor is associated with risk of venous thromboembolism and all-cause mortality in patients with cancer","volume":"43","author":"Englisch","year":"2023","journal-title":"H\u00e4mostaseologie"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1055\/s-2007-991531","article-title":"The role of tissue factor pathway inhibitor in tumor growth and metastasis","volume":"33","author":"Amirkhosravi","year":"2007","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Watanabe-Kusunoki, K., Nakazawa, D., Ishizu, A., and Atsumi, T. (2020). Thrombomodulin as a physiological modulator of intravascular injury. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.575890"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.transci.2019.06.008","article-title":"Revisiting the activated protein C-protein S-thrombomodulin ternary pathway: Impact of new understanding on its laboratory investigation","volume":"58","author":"Amiral","year":"2019","journal-title":"Transfus. Apher. Sci."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1161\/CIRCULATIONAHA.113.002702","article-title":"Venous thromboembolism and cancer","volume":"128","author":"Piazza","year":"2013","journal-title":"Circulation"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1007\/s13277-013-0958-x","article-title":"Thrombomodulin mediates the progression of epithelial ovarian cancer cells","volume":"34","author":"Chen","year":"2013","journal-title":"Tumor Biol."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Chang, Y.-J., Cheng, Y.-W., Lin, R.-K., Huang, C.-C., Chen, W.T.-L., Ke, T.-W., and Wei, P.-L. (2016). Thrombomodulin influences the survival of patients with non-metastatic colorectal cancer through epithelial-to-mesenchymal transition (EMT). PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0160550"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.bbrc.2016.05.105","article-title":"Thrombomodulin reduces tumorigenic and metastatic potential of lung cancer cells by up-regulation of E-cadherin and down-regulation of N-cadherin expression","volume":"476","author":"Zheng","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/ags3.12447","article-title":"Thrombomodulin expression impacts the recurrence and long-term survival in pancreatic cancer","volume":"5","author":"Sugano","year":"2021","journal-title":"Ann. Gastroenterol. Surg."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Huang, C.-Y., Wei, P.-L., Prince, G.S.H., Batzorig, U., Lee, C.-C., Chang, Y.-J., and Hung, C.-S. (2023). The role of thrombomodulin in estrogen-receptor-positive breast cancer progression, metastasis, and curcumin sensitivity. Biomedicines, 11.","DOI":"10.3390\/biomedicines11051384"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/13\/2356\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:06:10Z","timestamp":1760108770000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/13\/2356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,27]]},"references-count":97,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["cancers16132356"],"URL":"https:\/\/doi.org\/10.3390\/cancers16132356","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,27]]}}}